GlassScriptPhysician profile
Pareshkumar Patel
NPI 1184718496
$27,535.56
in general payments reported to CMS, 2019-2025
85 companies · $2,781 in 2025
The $2,781 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,920 · 2020: $2,157 · 2021: $2,089 · 2022: $1,892 · 2023: $2,059 · 2024: $12K · 2025: $2,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,558 · Food and Beverage: $7,021 · Travel and Lodging: $1,438 · Education: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,558.33 |
| Food and Beverage | $7,020.82 |
| Travel and Lodging | $1,438.33 |
| Education | $459.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,727.99 | 2019-2025 | |
| Verastem, INC. | $3,072.80 | 2019 | |
| Rigel Pharmaceuticals, INC. | $1,031.93 | 2020-2022 | |
| Seagen INC. | $966.67 | 2019-2022 | |
| Celgene Corporation | $905.27 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $817.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $793.44 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $709.46 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Jazz Pharmaceuticals INC. | $594.72 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $541.04 | 2019-2025 | Opdivo, Krazati |
| Astellas Pharma US INC | $518.37 | 2019-2025 | Padcev, Vyloy, Xospata |
| Ipsen Biopharmaceuticals, INC | $490.70 | 2022-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $474.05 | 2019-2025 | Libtayo |
| Genentech USA, INC. | $457.67 | 2019-2025 | Polivy, Venclexta, Itovebi |
| Glaxosmithkline, LLC. | $410.78 | 2020-2025 | Ojjaara, Jemperli, Zejula |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $407.87 | 2020-2025 | Talvey, Tecvayli, Darzalex |
| Octapharma USA, INC. | $396.18 | 2020-2024 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $362.10 | 2019-2025 | Enhertu, Datroway |
| Abbvie INC. | $360.31 | 2019-2025 | |
| Gilead Sciences, INC. | $325.18 | 2021-2025 | Trodelvy |
| Amgen INC. | $292.69 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Galvanize Therapeutics, INC | $221.28 | 2025 | Aliya System |
| Eisai INC. | $220.31 | 2019-2025 | |
| Exelixis INC. | $219.69 | 2020-2025 | Cabometyx |
| Incyte Corporation | $198.87 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $186.13 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Genzyme Corporation | $173.51 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $171.91 | 2023-2025 | Monoferric, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $164.53 | 2019-2025 | |
| Stemline Therapeutics INC. | $132.21 | 2020-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $130.36 | 2019-2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $128.35 | 2019-2022 | |
| Array Biopharma INC | $121.32 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.57 | 2021-2025 | Gilotrif |
| Johnson & Johnson Health Care Systems INC. | $115.94 | 2019 | |
| Karyopharm Therapeutics INC. | $89.03 | 2021-2025 | Xpovio |
| Sobi, INC | $85.09 | 2023-2025 | |
| Emd Serono, INC. | $84.58 | 2021-2025 | |
| Puma Biotechnology, INC. | $69.41 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $64.72 | 2023-2025 | Provenge |
| Taiho Oncology, INC. | $56.62 | 2023-2024 | |
| Coherus Oncology, INC. | $56.19 | 2021 | |
| Genmab U.S., INC. | $54.19 | 2025 | Epkinly |
| Amag Pharmaceuticals, INC. | $53.92 | 2019-2021 | |
| Kite Pharma, INC. | $53.10 | 2021-2023 | |
| Blueprint Medicines Corporation | $52.59 | 2021-2024 | Ayvakit |
| Lexicon Pharmaceuticals, INC. | $52.18 | 2019 | |
| Pharmaessentia USA Corporation | $48.06 | 2022-2025 | Besremi |
| Heron Therapeutics, INC. | $47.40 | 2020-2021 | |
| Csl Behring | $47.11 | 2021-2022 | |
| Chiesi USA, INC. | $44.40 | 2019-2025 | Kengreal |
| Deciphera Pharmaceuticals INC. | $40.92 | 2022-2025 | Romvimza, Qinlock |
| Sun Pharmaceutical Industries INC. | $38.65 | 2024 | |
| G1 Therapeutics, INC. | $35.44 | 2022 | |
| Aveo Pharmaceuticals, INC. | $31.72 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $30.21 | 2024 | |
| Lilly USA, LLC | $29.70 | 2022-2024 | Jaypirca, Verzenio |
| Ge Healthcare | $27.94 | 2022 | |
| Secura Bio, INC. | $27.80 | 2020 | |
| Acrotech Biopharma INC. | $25.45 | 2022 | |
| Grifols USA, LLC | $24.72 | 2019 | |
| Geron Corporation | $23.85 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $21.23 | 2025 | |
| Morphosys, US INC. | $20.57 | 2022 | |
| Immunogen, INC. | $19.84 | 2023 | Elahere |
| Cti Biopharma Corp. | $18.45 | 2023 | Vonjo |
| Legend Biotech USA INC. | $18.23 | 2025 | Carvykti |
| Emmaus Medical, INC. | $17.74 | 2021-2023 | Endari |
| Allergan, INC. | $17.61 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.93 | 2024 | Givlaari |
| Epizyme, INC. | $15.79 | 2021 | |
| Immunocore Limited | $14.54 | 2024 | Kimmtrak |
| Global Blood Therapeutics, INC. | $14.26 | 2021 | |
| Adaptive Biotechnologies Corporation | $14.11 | 2025 | Clonoseq |
| Novo Nordisk INC | $13.42 | 2021 | |
| Mirati Therapeutics, INC. | $13.39 | 2024 | Krazati |
| Nestle Healthcare Nutrition INC. | $12.78 | 2022 | |
| Janssen Scientific Affairs, LLC | $12.57 | 2019 | |
| Tg Therapeutics, INC. | $12.28 | 2022 | |
| Sirtex Medical INC | $7.01 | 2024 | Sir-Spheres Microspheres |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$356.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pareshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.